DEFA14A ·Filed Jun 9, 2026

HAE

HAEMONETICS CORP
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0000313143-26-000076
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for the definitive proxy statement (DEF 14A) and any dissident proxy materials (DFAN14A) to understand the specific activist demands and management's response. The amplifier verdicts suggest this proxy contest may have outsized impact relative to standalone reading.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
HAE ▲ +30.52% at T+60d
NEUTRAL call ✓ call won +30.52% · α vs SPY +23.94% · entry $78.80 → $102.85
Entry anchored
Jun 9, 03:59 PM ET
via exchange tick
T+1d
+1.32%
call +1.32% · α -0.38%
$79.84
settled 4mo ago
T+5d
-5.55%
call -5.55% · α -8.98%
$74.43
settled 4mo ago
T+20d
-4.82%
call -4.82% · α -8.45%
$75.00
settled 3mo ago
T+60d
+30.52%
call +30.52% · α +23.94%
$102.85
settled 29d ago

Price Chart

Loading chart...

Executive Summary

Haemonetics Corp filed definitive additional proxy soliciting materials (DEFA14A) on June 9, 2026, filed by management. The filing references an activist/dissident proxy context, with cross-filing actuarial verdicts confirming amplifier effects for dissident-proxy combinations. No specific financial figures, vote items, or activist demands are extractable from the document text provided.

Key Facts

  • Filed DEFA14A (definitive additional proxy materials) on June 9, 2026
  • Filed by the registrant (management) as indicated on Schedule 14A
  • Cross-filing context indicates dissident-proxy-activist-context and dissident-proxy-def14a-context
  • All cross-filing actuarial verdicts are AMPLIFIER (PMI=3.59, q=0.000, n=2127)
  • No fee required — fee paid previously with preliminary materials

Financial Impact

No financial figures disclosed in the filing

Risk Factors

  • Potential activist campaign could lead to board changes or strategic review
  • Uncertainty around specific proposals until definitive proxy is filed

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
73% bullish (15 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0000313143-26-000076
Document: 0000313143-26-000076-index-headers.html0000313143-26-000076
Document: 0000313143-26-000076-index.html0000313143-26-000076
Document: 0000313143-26-000076.txt0000313143-26-000076
5 reports for HAE
Performance horizon
Filters
Rows
Reports for HAE — sortable, filterable
TypeNow
Aug 18, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$104.65 $105.68▲ +0.98%▲ +1.97%$104.68 (+0.03%)
Jun 9, 2026
16w ago
DEFA14A
NEUTRAL ★ 5/10
$78.80 $75.00▼ −4.82%▼ −8.45%$104.68 (+32.84%)
Jun 5, 2026
17w ago
8-K
NEUTRAL ★ 2/10
$71.28 $75.02▲ +5.25%▲ +3.39%$104.68 (+46.86%)
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$54.37 $65.88▲ +21.17%▲ +18.03%$104.68 (+92.53%)
May 1, 2026
22w ago
8-K
NEUTRAL ★ 2/10
$55.32 $67.22▲ +21.51%▲ +15.87%$104.68 (+89.23%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (64h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access